Standard BioTools Inc. (LAB)

Standard BioTools Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-74.66	-190.1	-59.24	-53.02	-64.79
Depreciation & Amortization	3.98	3.5	3.65	6.03	4.09
Share-Based Compensation	13.12	14.88	16.1	14.45	11.39
Other Operating Activities	14.27	82.35	-4.58	17.12	14.1
Operating Cash Flow	-43.29	-89.37	-44.06	-15.42	-35.21
Capital Expenditures	-2.83	-3.83	-13.26	-12.72	-2.53
Acquisitions	0	0	1.32	15.88	0
Change in Investments	23.07	-84.3	0	36.81	-36.77
Investing Cash Flow	20.24	-88.13	-11.95	39.98	-39.3
Share Issuance / Repurchase	-4.59	0.35	1.49	22	2.13
Debt Issued / Paid	-2.08	18.16	16.34	0	3.17
Other Financing Activities	-0.14	212.24	-1.87	-1.14	-2.52
Financing Cash Flow	-6.81	230.76	15.96	20.86	2.79
Exchange Rate Effect	0.03	-0.4	-0.02	0.39	0.06
Net Cash Flow	-29.83	52.86	-40.07	45.8	-71.67
Free Cash Flow	-46.12	-93.2	-57.33	-28.13	-37.74
Free Cash Flow Margin	-43.37%	-95.15%	-43.90%	-20.37%	-32.19%
Free Cash Flow Per Share	-0.58	-1.19	-0.76	-0.39	-0.56

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).